Skip to content 
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. more
| Time Frame | MOLN | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 1.02% | -2.23% | -1.13% |
| 1-Month Return | 6.94% | -0.6% | 0.6% |
| 3-Month Return | 9.07% | 0.42% | -0.58% |
| 6-Month Return | 37.71% | 11.61% | 5.35% |
| 1-Year Return | 0.61% | 2.83% | 16.85% |
| 3-Year Return | -17.56% | 19.21% | 68.62% |
| 5-Year Return | -74.91% | 36.18% | 77.72% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 9.34M | 9.33M | 189.56M | 7.04M | 4.97M | [{"date":"2020-12-31","value":4.93,"profit":true},{"date":"2021-12-31","value":4.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":3.71,"profit":true},{"date":"2024-12-31","value":2.62,"profit":true}] |
| Cost of Revenue | 56.08M | 55.72M | 50.75M | 47.84M | 47.50M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.36,"profit":true},{"date":"2022-12-31","value":90.5,"profit":true},{"date":"2023-12-31","value":85.32,"profit":true},{"date":"2024-12-31","value":84.72,"profit":true}] |
| Gross Profit | (46.73M) | (46.39M) | 138.81M | (40.81M) | (42.53M) | [{"date":"2020-12-31","value":-33.67,"profit":false},{"date":"2021-12-31","value":-33.42,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-29.4,"profit":false},{"date":"2024-12-31","value":-30.64,"profit":false}] |
| Gross Margin | (500.12%) | (497.19%) | 73.23% | (579.80%) | (855.81%) | [{"date":"2020-12-31","value":-682.96,"profit":false},{"date":"2021-12-31","value":-678.97,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-791.77,"profit":false},{"date":"2024-12-31","value":-1168.71,"profit":false}] |
| Operating Expenses | 67.67M | 72.75M | 72.94M | 20.30M | 18.68M | [{"date":"2020-12-31","value":92.77,"profit":true},{"date":"2021-12-31","value":99.73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":27.83,"profit":true},{"date":"2024-12-31","value":25.61,"profit":true}] |
| Operating Income | (58.33M) | (63.42M) | 116.61M | (61.11M) | (61.22M) | [{"date":"2020-12-31","value":-50.02,"profit":false},{"date":"2021-12-31","value":-54.38,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-52.4,"profit":false},{"date":"2024-12-31","value":-52.5,"profit":false}] |
| Total Non-Operating Income/Expense | (4.38M) | (822.00K) | 1.76M | 2.86M | 10.52M | [{"date":"2020-12-31","value":-41.67,"profit":false},{"date":"2021-12-31","value":-7.81,"profit":false},{"date":"2022-12-31","value":16.76,"profit":true},{"date":"2023-12-31","value":27.22,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Pre-Tax Income | (62.77M) | (63.78M) | 117.85M | (61.98M) | (54.04M) | [{"date":"2020-12-31","value":-53.27,"profit":false},{"date":"2021-12-31","value":-54.12,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-52.59,"profit":false},{"date":"2024-12-31","value":-45.85,"profit":false}] |
| Income Taxes | (11.00K) | 2.00K | (717.00K) | 2.25M | 2.00K | [{"date":"2020-12-31","value":-0.49,"profit":false},{"date":"2021-12-31","value":0.09,"profit":true},{"date":"2022-12-31","value":-31.84,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":0.09,"profit":true}] |
| Income After Taxes | (62.76M) | (63.78M) | 118.57M | (64.24M) | (54.04M) | [{"date":"2020-12-31","value":-52.93,"profit":false},{"date":"2021-12-31","value":-53.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-54.18,"profit":false},{"date":"2024-12-31","value":-45.58,"profit":false}] |
| Income From Continuous Operations | (62.76M) | (63.78M) | 117.85M | (59.63M) | (54.04M) | [{"date":"2020-12-31","value":-53.26,"profit":false},{"date":"2021-12-31","value":-54.12,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-50.6,"profit":false},{"date":"2024-12-31","value":-45.86,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (62.76M) | (63.78M) | 117.85M | (61.98M) | (54.04M) | [{"date":"2020-12-31","value":-53.26,"profit":false},{"date":"2021-12-31","value":-54.12,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-52.59,"profit":false},{"date":"2024-12-31","value":-45.86,"profit":false}] |
| EPS (Diluted) | (2.56) | (2.40) | 8.25 | (2.03) | (1.92) | [{"date":"2020-12-31","value":-31.11,"profit":false},{"date":"2021-12-31","value":-29.13,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-24.58,"profit":false},{"date":"2024-12-31","value":-23.32,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| MOLN | |
|---|---|
| Cash Ratio | 8.90 |
| Current Ratio | 9.28 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| MOLN | |
|---|---|
| ROA (LTM) | -27.01% |
| ROE (LTM) | -51.42% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| MOLN | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.15 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| MOLN | |
|---|---|
| Trailing PE | NM |
| Forward PE | 1.78 |
| P/S (TTM) | 199.56 |
| P/B | 1.55 |
| Price/FCF | NM |
| EV/R | 0.95 |
| EV/Ebitda | 1.23 |
Molecular Partners AG ADR (MOLN) share price today is $5.105
Yes, Indians can buy shares of Molecular Partners AG ADR (MOLN) on Vested. To buy
Yes, you can purchase fractional shares of Molecular Partners AG ADR (MOLN) via the Vested app. You can start investing in Molecular Partners AG ADR (MOLN) with a minimum investment of $1.
You can invest in shares of Molecular Partners AG ADR (MOLN) via Vested in three simple steps:
The 52-week high price of Molecular Partners AG ADR (MOLN) is $5.36. The 52-week low price of Molecular Partners AG ADR (MOLN) is $3.36.
The price-to-earnings (P/E) ratio of Molecular Partners AG ADR (MOLN) is
The price-to-book (P/B) ratio of Molecular Partners AG ADR (MOLN) is 1.55
The dividend yield of Molecular Partners AG ADR (MOLN) is 0.00%
The market capitalization of Molecular Partners AG ADR (MOLN) is $184.38M
The stock symbol (or ticker) of Molecular Partners AG ADR is MOLN
Consider the share price of Molecular Partners AG ADR as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Molecular Partners AG ADR has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Molecular Partners AG ADR shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Molecular Partners AG ADR stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Molecular Partners AG ADR and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Molecular Partners AG ADR stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
